Form 4: Theravance CFO's Tax-Related Stock Disposal

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 20,672 ordinary shares to cover tax obligations from vested restricted stock units.

Summary

• Aziz Sawaf, SVP & Chief Financial Officer of Theravance Biopharma, Inc. (TBPH), reported a transaction on February 20, 2026.
• The transaction involved the disposition of 20,672 ordinary shares at a price of $19.66 per share.
• These shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• This was not an open market transaction but an administrative withholding with the issuer.
• Following this transaction, Aziz Sawaf beneficially owns 316,123 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine administrative transaction for tax purposes rather than an indicator of fundamental company performance or a change in insider sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that tax-related share disposals are a common and routine occurrence for executives receiving equity compensation, such as restricted stock units. These transactions are typically administrative and generally do not reflect a change in management's sentiment towards the company's future prospects or operational performance within the biopharmaceutical industry.

Related Party Transactions

• Shares were withheld by the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations arising from the vesting of restricted stock units, which is a transaction with a related party but is a standard administrative process for equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine administrative transaction related to executive compensation and not an open market sale or a reflection of company performance.

Key Dates

Recommendation

This Form 4 reports a routine tax-related share disposition by a company officer, which does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as it reflects no significant change in the company's outlook based on this filing.

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Stock Disposal, Tax Withholding, Restricted Stock Units, RSU, Aziz Sawaf